Outcomes of Arterial Allografts Preserved at +2 to +8°C for Revascularization in Septic Settings

Condition(s) studied

Investigational drug(s) / intervention(s)

arterial revascularization: arterial revascularization

Study summary

This study does not modify patient management or treatment. All patients undergoing treatment with an arterial allograft preserved at +2/+8°C as part of an arterial revascularization in a septic environment in either of the two centers between January 2024 and January 2025 will be included.

Imaging exams and clinical follow-up data will be analyzed. Reinterventions and causes of death will be recorded. All imaging required for the 6-month follow-up is routinely performed as part of standard care. No modification of patient management is planned.

Eligibility

Primary outcome measure(s)

• To evaluate the 6-month primary patency of revascularizations using arterial allografts preserved at +2 to +8°C — 6 month
  Evaluation of the 6-month primary patency of the revascularization, defined as the percentage of patients with a patent bypass without reintervention or \>50% stenosis, confirmed by a morphological imaging exam (Doppler ultrasound or CT angiography) performed at 6 months

Trial sites (2)

More Hospices Civils de Lyon trials in France